{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:05:58Z","timestamp":1781715958147,"version":"3.54.5"},"reference-count":7,"publisher":"Norwegian Medical Association","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.25.0229","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:00:10Z","timestamp":1758542410000},"source":"Crossref","is-referenced-by-count":1,"title":["Kolestase etter bruk av fenbendazol som alternativ behandling mot kreft"],"prefix":"10.4045","volume":"145","author":[{"given":"Turid Rygh","family":"Skaara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie Delphin","family":"Amdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jespersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simen Kjeka","family":"Namtvedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"ref=1","unstructured":"Jeppesen E, Juvet LK. Komplement\u00e6r og alternativ behandling for pasienter med kreft. Rapport fra Kunnskapssenteret nr 12-2011. Systematisk oversikt. https:\/\/www.fhi.no\/globalassets\/dokumenterfiler\/rapporter\/2011\/rapport_2011_12_-kam.pdf Lest 24.6.2025."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Haanen\u00a0J, Obeid\u00a0M, Spain\u00a0L et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217\u201338. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36270461&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.annonc.2022.10.001","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"ref=3","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Cemiplimab. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548288\/ Lest 29.3.2025."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Thorsteinsdottir\u00a0T, L\u00f8iteg\u00e5rd\u00a0T, Reims\u00a0HM et al. Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report. Case Rep Oncol 2020; 13: 659\u201363. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32774252&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1159%2F000507695","DOI":"10.1159\/000507695"},{"key":"ref=5","unstructured":"Duan\u00a0Q, Liu\u00a0Y, Rockwell\u00a0S. Fenbendazole as a potential anticancer drug. Anticancer Res 2013; 33: 355\u201362. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23393324&dopt=Abstract"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Thakurdesai\u00a0A, Rivera-Matos\u00a0L, Nagra\u00a0N et al. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole. ACG Case Rep J 2024; 11: e01354. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38706451&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.14309%2Fcrj.0000000000001354","DOI":"10.14309\/crj.0000000000001354"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Yamaguchi\u00a0T, Shimizu\u00a0J, Oya\u00a0Y et al. Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information. Case Rep Oncol 2021; 14: 886\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34248555&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1159%2F000516276","DOI":"10.1159\/000516276"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:21:40Z","timestamp":1781713300000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2025\/09\/kort-kasuistikk\/kolestase-etter-bruk-av-fenbendazol-som-alternativ-behandling-mot-kreft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.25.0229","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}